Cardiology

Measures of heart function and anatomy were used to assess the effects of red and processed meat on cardiovascular health; findings were reported at ESC Preventive Cardiology 2021.

The indicator of vascular protection against atherosclerotic progression was inversely associated with incident CV events, independent of traditional CVD biomarkers and improved Framingham Risk Score prediction.

Post-hoc analysis of the SPRINT trial found greater time spent with systolic blood pressure in target range was significantly associated with decreased risk of MACE.

Jackson Heart Study participants who maintained a healthy BP, BMI, and never smoked were at lower risk for incident CVD, suggesting targets for intervention in high-risk populations.

In individuals with chronic coronary disease, the presence of diabetes increased the rate of death by 38% during a 5-year follow-up period in analysis of a worldwide patient registry.

A recent meta-analysis suggests some sodium glucose cotransporter-2 inhibitor agents may protect against atrial and ventricular arrhythmias as well as sudden cardiac death in type 2 diabetes patients.

Healthcare providers are advised to weigh carefully the risks vs benefits of continuing lamotrigine therapy and not to substitute with another drug from the class.

In a subanalysis of the landmark DAPA-HF trial, dapagliflozin benefits were observed in both men and women, an important finding given variable response to cardiovascular drugs among women.

Influenza vaccination is associated with lower risk for all-cause and cardiovascular death in patients with CVD vs no vaccination, a new meta-analysis found.

The new consensus document is the first to offer personalized advice on the most effective exercises to lower blood pressure based on a patient's current blood pressure level.

ENDO 2021: A meta-analysis found increased cardiometabolic risk among Black women with PCOS vs White counterparts even though fasting glucose levels were comparable and triglyceride levels lower.

ENDO 2021: Obese individuals treated with semaglutide 2.4 mg vs placebo demonstrated improvements in body composition paralleling weight loss that may reduce risk for cardiometabolic disease.

Preliminary findings being presented at the International Stroke Conference 2021 show some of the same risk factors associated with stroke in older adults also cause stroke in younger adults.

International Stroke Conference 2021: A new analysis of the landmark REDUCE-IT trial found that adding icosapent ethyl to treatment regimens that already include statins further reduces stroke risk.

Suspicion for ACS in women was lower than that for men even in the presence of significant risk factors for heart attack, study authors report.

Stroke patients are nearly 50% more likely vs heart attack patients to develop depression, according to new research being presented at the upcoming International Stroke Conference.

Using metabolomic profiling from more than 11 000 individuals, researchers identified common pathways linking seemingly unrelated diseases that often co-occur.

A new study suggests that women who experience an accelerated accumulation of abdominal fat during menopause are at greater risk of heart disease, even if their weight stays steady.

FDA approved the fixed-dose combination heart failure drug sacubitril/valsartan to reduce risk of CV death and hospitalization in patients with chronic heart failure.

To ensure COVID-19 vaccination priority for the sickest CVD patients, the ACC statement identifies highest risk conditions within CVD to aid clinician decision making.

Variability in A1c during the first 2 years after T2D diagnosis is a strong predictor of CV disease; study authors note the risk may be mediated by severe hypoglycemic episodes.

Heart disease, again the leading cause of death worldwide, may remain so for many years as a result of COVID-19 pandemic conditions, says AHA Update Writing Committee Chair.

Video: George Bakris, MD says over the next 3 years there is going to be an "explosion" in the number of studies we see in heart failure, diabetic kidney disease, and CV risk in general.

The FDA approved vericiguat to reduce the risk of CV death and rehospitalization for HF in HF patients after hospital discharge or after outpatient treatment with IV diuretics.

Physical activity cannot compensate adequately for the negative impact of excess body weight on cardiometabolic health.